摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,3-二甲基-1H-吡唑-4-胺双盐酸盐 | 197367-87-6

中文名称
1,3-二甲基-1H-吡唑-4-胺双盐酸盐
中文别名
氨基吡唑二盐酸盐;1,3-二甲基-4-氨基吡唑双盐酸盐;1,3-二甲基-4-氨基吡唑二盐酸盐;1,3-二甲基-1H-吡唑-4-胺二盐酸盐
英文名称
1,3-Dimethyl-1H-pyrazol-4-amine dihydrochloride
英文别名
1,3-dimethylpyrazol-4-amine;dihydrochloride
1,3-二甲基-1H-吡唑-4-胺双盐酸盐化学式
CAS
197367-87-6
化学式
C5H11Cl2N3
mdl
——
分子量
184.06
InChiKey
DWNGGFJVARNXSR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.15
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    43.8
  • 氢给体数:
    3
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2933199090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

制备方法与用途

1,3-二甲基-1H-吡唑-4-胺二盐酸盐是一种有机中间体,可由4,4-二甲氧基-2-丁酮与甲基肼先制备二甲基吡唑,然后硝化还原得到。

文献信息

  • [EN] THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE<br/>[FR] DÉRIVÉS DE THIOPHÈNE POUR LE TRAITEMENT DE TROUBLES PROVOQUÉS PAR IGE
    申请人:UCB BIOPHARMA SRL
    公开号:WO2019243550A1
    公开(公告)日:2019-12-26
    Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.
    提供了公式(I)的噻吩生物及其药用可接受的盐。这些化合物对于治疗或预防由IgE引起的疾病具有用途,如过敏、1型超敏反应或家族性鼻窦炎。
  • HETEROCYCLIC COMPOUND
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP2832734A1
    公开(公告)日:2015-02-04
    The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    本发明提供了一种用于预防或治疗自身免疫性疾病(例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等)等的药剂,其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的那样,或其盐。
  • CYCLOPROPANAMINE COMPOUND AND USE THEREOF
    申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
    公开号:US20150266881A1
    公开(公告)日:2015-09-24
    The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R 1 , R 2 and R 3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R 1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R 2 and R 3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.
    本发明提供一种具有赖酸特异性去甲基化酶1抑制作用的化合物,可用作预防或治疗精神分裂症、阿尔茨海默病、帕森病或亨廷顿病等疾病的药物。本发明涉及一种由下式表示的化合物: 其中A是一个烃基,可选地具有取代基,或者是一个杂环基,可选地具有取代基;B是一个环,可选地具有进一步的取代基;R1、R2和R3分别是原子,或者是一个烃基,可选地具有取代基,或者是一个杂环基,可选地具有取代基;A和R1可选地结合在一起,与相邻的原子一起形成一个可选地具有取代基的环基;而R2和R3可选地结合在一起,与相邻的原子一起形成一个可选地具有取代基的环基,或其盐。
  • Compounds and methods for kinase modulation, and indications therefor
    申请人:Plexxikon Inc.
    公开号:US10829484B2
    公开(公告)日:2020-11-10
    Compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein A, J, R1, R2, R3, R4, R5, R6, R7, R9, X, m and n are as described herein, compositions thereof, and methods and uses thereof.
    式 I 的化合物: 或其药学上可接受的盐、溶解物、同分异构体、异构体或氚代类似物,其中 A、J、R1、R2、R3、R4、R5、R6、R7、R9、X、m 和 n 如本文所述;其组合物及其方法和用途。
  • SUBSTITUTED 7-OXO-PYRIDO [2, 3-D]PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS
    申请人:Amgen Inc.
    公开号:EP2961750A1
    公开(公告)日:2016-01-06
查看更多